18:00:08 EST Sat 21 Nov 2026
Enter Symbol
or Name
USA
CA



Q:CYTK - CYTOKINETICS INC - https://www.cytokinetics.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
CYTK - Q0.145.58·53.700.150.78-0.68-1.31,426.772,41314,31051.27  53.45  50.6088.31  50.3219:38:39Nov 1615 min RT 2¢

Recent Trades - Last 10 of 14310
Time ETExPriceChangeVolume
19:38:39Q52.48091.02093,000
19:36:06Q51.500.044
19:30:06Q50.609-0.8511
19:30:06Q50.609-0.8511
19:30:06Q50.609-0.8511
19:30:05Q50.609-0.8511
19:30:05Q50.609-0.8511
18:29:59Q50.60-0.8640
17:56:54Q51.20-0.261
17:47:38Q50.69-0.7710

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-11-16 16:00U:CYTKNews ReleaseCytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-11-16 04:00U:CYTKNews ReleaseCytokinetics Announces Prescribing Information for MYQORZO(TM) (aficamten) Expanded to Include Data from Phase 3 MAPLE-HCM
2026-11-09 07:30U:CYTKNews ReleaseCytokinetics Announces Additional Data Related to Aficamten Presented at the Hypertrophic Cardiomyopathy Medical Society (HCMS) Scientific Sessions Held in Collaboration with the American Heart Association Scientific Sessions 2026
2026-11-04 16:00U:CYTKNews ReleaseCytokinetics Reports Third Quarter 2026 Financial Results and Provides Business Update
2026-11-03 16:00U:CYTKNews ReleaseCytokinetics to Participate in November Investor Conferences
2026-11-02 07:30U:CYTKNews ReleaseCytokinetics Announces Three Upcoming Presentations at the Hypertrophic Cardiomyopathy Medical Society (HCMS) Scientific Sessions Held in Collaboration with the American Heart Association Scientific Sessions 2026
2026-10-21 16:00U:CYTKNews ReleaseCytokinetics to Announce Third Quarter Results on November 4, 2026
2026-10-19 16:00U:CYTKNews ReleaseCytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-10-19 07:30U:CYTKNews ReleaseCytokinetics Announces Health Canada Approval of MYQORZO(TM) (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy
2026-10-12 16:00U:CYTKNews ReleaseCytokinetics Announces Additional Data from ACACIA-HCM Presented at the HFSA Annual Scientific Meeting 2026
2026-10-02 07:30U:CYTKNews ReleaseCytokinetics Announces Four Upcoming Presentations at the HFSA Annual Scientific Meeting 2026
2026-09-30 07:30U:CYTKNews ReleaseCytokinetics Launches ASPEN-HCM: A Real-World Study Evaluating MYQORZO(TM) (aficamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy
2026-09-17 16:00U:CYTKNews ReleaseCytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-09-14 07:30U:CYTKNews ReleaseCytokinetics Announces Call for Proposals for Ninth Annual Communications Grant Program
2026-09-02 16:00U:CYTKNews ReleaseCytokinetics to Participate in September Investor Conferences
2026-08-29 10:30U:CYTKNews ReleaseCytokinetics Announces Additional Results from ACACIA-HCM and MAPLE-HCM Presented in Late Breaking Clinical Trial Session at the European Society of Cardiology (ESC) Congress 2026
2026-08-28 05:45U:CYTKNews ReleaseCytokinetics Announces Positive Results from ACACIA-HCM Presented in Hot Line Session at the European Society of Cardiology (ESC) Congress 2026 and Published in The New England Journal of Medicine
2026-08-20 07:30U:CYTKNews ReleaseCytokinetics Announces Upcoming Presentations at the European Society of Cardiology (ESC) Congress 2026
2026-08-18 16:00U:CYTKNews ReleaseCytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-08-06 16:00U:CYTKNews ReleaseCytokinetics Reports Second Quarter 2026 Financial Results and Provides Business Update